AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00539305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel
Description: 50-100mg applied topically daily for six months
Study NCT00539305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: applied topically daily for six months
Study NCT00711971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPA-rich fish oil supplement
Description: 1060 mg EPA plus 274 mg DHA
Study NCT00711971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich fish oil supplement
Description: 900 mg DHA plus 180 mg EPA
Study NCT00711971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: control arm
Study NCT01104727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4-Ports Cholecystectomy (4PC)
Description: a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
Study NCT01104727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Port Cholecystectomy (SPC)
Description: a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones.
Study NCT04312347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen dose adjustment
Description: Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
Study NCT01177189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamins C, E, and alpha lipoic acid
Description: Oral antioxidant cocktail or placebo to be consumed daily
Study NCT03908359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional cataract surgery
Description: ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
Study NCT03908359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal invasive lens surgery
Description: We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
Study NCT00550381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule
Study NCT01711450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Description: Injection of local anaesthesia into paravertebral space to provide analgesia
Study NCT01711450 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control sham procedure
Description: Injection of Normal saline into the paravertebral space
Study NCT02229929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A: Placebo
Description: Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
Study NCT02229929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: CR845 0.5 mcg/kg
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Study NCT02229929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: CR845 1.0 mcg/kg
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Study NCT02229929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: CR845 2.5 mcg/kg
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Study NCT02229929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part B: Placebo
Description: Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
Study NCT02229929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: CR845 1.0 mcg/kg
Description: Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
Study NCT00793325 — intervention group
Intervention type: DRUG
Intervention: Somatropin
Description: Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route.
Study NCT02751476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Use (PoU) water treatment flocculent disinfectant.
Description: A household level point of use water treatment of a flocculent disinfectant will be tested.
Study NCT02751476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Use (PoU) water treatment chlorine disinfectant
Description: A household level point of use water treatment of a chlorine disinfectant will be tested.
Study NCT02751476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of Use (PoU) ceramic water filter
Description: A household level point of use water treatment of a ceramic water filter will be tested.
Study NCT02751476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Severe Acute Malnutrition Treatment
Description: Standard CMAM treatment.
Study NCT02751476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Severe Acute Malnutrition Treatment
Description: Standard CMAM treatment.
Study NCT00390039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Morphine
Description: MNS075 7.5mg q1h PRN
Study NCT00390039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IN Placebo q1h PRN
Study NCT00390039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine
Description: IV morphine 7.5mg q3h PRN
Study NCT02546193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
Study NCT03217565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Tedizolid Phosphate
Description: A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
Study NCT03217565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Suspension Tedizolid Phosphate
Description: A single dose of tedizolid phosphate administered as an oral suspension.
Study NCT05642689 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Iron fortified milk with iron salt labelled with 58Fe and 57Fe
Description: Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
Study NCT03518996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS/iTBS/tACS
Description: Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
Study NCT03518996 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS/tACS
Description: Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
Study NCT02063802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
Study NCT02063802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid
Description: total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
Study NCT02063802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
Study NCT02063802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy habits program
Study NCT02063802 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy habits program
Study NCT01996514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV program with non-food advertisements while feeding
Description: 30 minutes of TV program containing non-food ads during a meal
Study NCT02063802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy habits program
Study NCT04160884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green Injection through Peripheral Vein
Description: After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
Study NCT04160884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Injection through Peripheral Vein
Description: After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
Study NCT02978300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV/HFNC
Description: Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
Study NCT02978300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
Study NCT01996514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV program with food advertisements while feeding
Description: 30 minutes of TV program containing non-food ads during a meal
Study NCT02962999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
Study NCT02962999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
Study NCT03188458 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 \[approximately 4-8 weeks of age\]).
Study NCT03993002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normoxia with Normocarbia
Description: PaO2 \< 100 (FiO2 >= 21%) PaCO2 of 30-40
Study NCT03993002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normoxia with Hypercarbia
Description: PaO2 \< 100 (FiO2 >= 21%) PaCO2 of 50-60
Study NCT03993002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia with Normocarbia
Description: PaO2 > 250 (FiO2 >= 70%) PaCO2 of 30-40
Study NCT03993002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia with Hypercarbia
Description: PaO2 > 250 (FiO2 >= 70%) PaCO2 of 50-60
Study NCT03154424 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: External fixation in treatment the distal radius fracture
Description: Compare two techniques
Study NCT03154424 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External fixation in treatment the distal radius fracture
Description: Compare two techniques
Study NCT00490828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone
Study NCT00490828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone
Study NCT02103400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Exercise Training Group
Study NCT02103400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Exercise control group
Study NCT01041742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid loading
Description: fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
Study NCT03264560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Description: A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
Study NCT03264560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychiatry
Description: A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
Study NCT04134247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 combined with chemotherapy
Description: PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3
Study NCT04134247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3
Study NCT01851720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose fentanyl PCA
Study NCT01851720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV fentanyl bolus
Study NCT00870363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)
Description: maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
Study NCT00870363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)
Description: maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
Study NCT00870363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
Description: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
Study NCT03646110 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive esophagectomy
Description: Minimally invasive esophagectomy is a surgical procedure for esophageal resection
Study NCT03646110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy
Description: Minimally invasive esophagectomy is a surgical procedure for esophageal resection
Study NCT03974815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTIVE
Description: We will use 28.26cm\^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials.
Study NCT03974815 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: We will use 28.26cm\^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials.
Study NCT03674060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYO-1644
Description: 100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet
Study NCT04177849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF
Description: A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.
Study NCT04177849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PF
Description: A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
Study NCT04780906 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Wrist taping
Description: Wrist taping as used as standard in CrossFit practice
Study NCT03674060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexavar tab
Description: Nexavar 200mg/tablet, PO, 1 tablet
Study NCT01613781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TOF count-guided partial NMB
Description: TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
Study NCT01613781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T1/Tc guided partial NMB
Description: Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
Study NCT01112527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Taken orally once a day
Study NCT01515800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminder
Description: Receive text message
Study NCT02636465 — intervention group
Intervention type: OTHER
Intervention: flight simulationin obese healthy adults or obese patients with or without COPD, OHS
Study NCT01217060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
Study NCT01217060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
Study NCT01217060 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.